Phase 1 Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
Price : $35 *
At a glance
- Drugs PFK 158 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Advanced Cancer Therapeutics
- 22 Jun 2015 According to the ClinicalTrials.gov record, planned number of patients changed from 54 to 56.
- 22 Jun 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jun 2015 to 1 Sep 2015.
- 27 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.